STOCK TITAN

Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. director Timothy Van Hauwermeiren received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, assuming he continues in service through that date. Following this award, he holds options on 35,000 shares directly.

Positive

  • None.

Negative

  • None.
Insider Van Hauwermeiren Timothy
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 35,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 35,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 35,000 shares Stock options on common stock granted to director
Exercise price $4.70 per share Stock option exercise price
Expiration date June 24, 2036 Option expiry for granted stock options
Post-transaction options held 35,000 shares Total derivative securities following transaction
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 4.7000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-24T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"100% of the shares underlying the option shall vest, and become exercisable"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of stockholders financial
"on the earlier of one year following the grant date or the next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Van Hauwermeiren Timothy

(Last)(First)(Middle)
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6

(Street)
NEW YORK NEW YORK 10010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$4.706/25/2026A35,000 (1)06/24/2036Common Stock35,000$035,000D
Explanation of Responses:
1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.
/s/ Youjin Choi, Attorney-in-Fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Lexeo Therapeutics (LXEO) report for Timothy Van Hauwermeiren?

Lexeo Therapeutics reported that director Timothy Van Hauwermeiren received a grant of stock options for 35,000 shares. These options are a compensation award, not an open-market share purchase or sale, and give the right to buy common stock at a fixed price in the future.

What is the exercise price of the new Lexeo Therapeutics (LXEO) stock options?

The granted options have an exercise price of $4.70 per share. This means Van Hauwermeiren can buy Lexeo Therapeutics common stock at $4.70 if he exercises the options after they vest and before they expire, regardless of the market price at that time.

When do Timothy Van Hauwermeiren’s Lexeo Therapeutics (LXEO) options vest?

All 35,000 shares underlying the option will vest on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting requires his continuous service as a director through that vesting date, according to the Form 4 footnote.

When do the newly granted Lexeo Therapeutics (LXEO) stock options expire?

The stock options granted to Timothy Van Hauwermeiren expire on June 24, 2036. He can exercise them only after they vest and before this expiration date; after expiration, any unexercised options would no longer be usable to acquire shares.

How many Lexeo Therapeutics (LXEO) options does Timothy Van Hauwermeiren hold after this grant?

After this transaction, he holds stock options covering 35,000 shares of Lexeo Therapeutics common stock. This reflects the full amount of the new award reported, with no additional derivative positions shown in the filing’s derivative position summary section.